Tags

Type your tag names separated by a space and hit enter

Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia.
Clin Infect Dis. 2002 Oct 01; 35(7):825-33.CI

Abstract

The increasing prevalence of resistance to antimalarial drugs reduces options for malaria prophylaxis. Atovaquone/proguanil (Malarone; GlaxoSmithKline) has been >95% effective in preventing Plasmodium falciparum malaria in lifelong residents of areas of holoendemicity, but data from persons without clinical immunity or who are at risk for Plasmodium vivax malaria have not been described. We conducted a randomized, double-blinded study involving 297 people from areas of nonendemicity in Indonesia who migrated to Papua (where malaria is endemic) < or =26 months before the study period. Subjects received prophylaxis with 1 Malarone tablet (250 mg of atovaquone and 100 mg of proguanil hydrochloride; n=148) or placebo (n=149) per day for 20 weeks. Hematologic and clinical chemistry values did not change significantly. The protective efficacy of atovaquone/proguanil was 84% (95% confidence interval [CI], 44%-95%) for P. vivax malaria, 96% (95% CI, 72%-99%) for P. falciparum malaria, and 93% (95% CI, 77%-98%) overall. Atovaquone/proguanil was well tolerated, safe, and effective for the prevention of drug-resistant P. vivax and P. falciparum malaria in individuals without prior malaria exposure who migrated to Papua, Indonesia.

Authors+Show Affiliations

Naval Medical Research Unit 2, Jakarta, Indonesia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

12228819

Citation

Ling, Judith, et al. "Randomized, Placebo-controlled Trial of Atovaquone/proguanil for the Prevention of Plasmodium Falciparum or Plasmodium Vivax Malaria Among Migrants to Papua, Indonesia." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 35, no. 7, 2002, pp. 825-33.
Ling J, Baird JK, Fryauff DJ, et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis. 2002;35(7):825-33.
Ling, J., Baird, J. K., Fryauff, D. J., Sismadi, P., Bangs, M. J., Lacy, M., Barcus, M. J., Gramzinski, R., Maguire, J. D., Kumusumangsih, M., Miller, G. B., Jones, T. R., Chulay, J. D., & Hoffman, S. L. (2002). Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 35(7), 825-33.
Ling J, et al. Randomized, Placebo-controlled Trial of Atovaquone/proguanil for the Prevention of Plasmodium Falciparum or Plasmodium Vivax Malaria Among Migrants to Papua, Indonesia. Clin Infect Dis. 2002 Oct 1;35(7):825-33. PubMed PMID: 12228819.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. AU - Ling,Judith, AU - Baird,J Kevin, AU - Fryauff,David J, AU - Sismadi,Priyanto, AU - Bangs,Michael J, AU - Lacy,Mark, AU - Barcus,Mazie J, AU - Gramzinski,Robert, AU - Maguire,Jason D, AU - Kumusumangsih,Marti, AU - Miller,Gerri B, AU - Jones,Trevor R, AU - Chulay,Jeffrey D, AU - Hoffman,Stephen L, AU - ,, Y1 - 2002/09/11/ PY - 2002/03/19/received PY - 2002/05/20/revised PY - 2002/9/14/pubmed PY - 2002/10/4/medline PY - 2002/9/14/entrez SP - 825 EP - 33 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 35 IS - 7 N2 - The increasing prevalence of resistance to antimalarial drugs reduces options for malaria prophylaxis. Atovaquone/proguanil (Malarone; GlaxoSmithKline) has been >95% effective in preventing Plasmodium falciparum malaria in lifelong residents of areas of holoendemicity, but data from persons without clinical immunity or who are at risk for Plasmodium vivax malaria have not been described. We conducted a randomized, double-blinded study involving 297 people from areas of nonendemicity in Indonesia who migrated to Papua (where malaria is endemic) < or =26 months before the study period. Subjects received prophylaxis with 1 Malarone tablet (250 mg of atovaquone and 100 mg of proguanil hydrochloride; n=148) or placebo (n=149) per day for 20 weeks. Hematologic and clinical chemistry values did not change significantly. The protective efficacy of atovaquone/proguanil was 84% (95% confidence interval [CI], 44%-95%) for P. vivax malaria, 96% (95% CI, 72%-99%) for P. falciparum malaria, and 93% (95% CI, 77%-98%) overall. Atovaquone/proguanil was well tolerated, safe, and effective for the prevention of drug-resistant P. vivax and P. falciparum malaria in individuals without prior malaria exposure who migrated to Papua, Indonesia. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/12228819/Randomized_placebo_controlled_trial_of_atovaquone/proguanil_for_the_prevention_of_Plasmodium_falciparum_or_Plasmodium_vivax_malaria_among_migrants_to_Papua_Indonesia_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/342578 DB - PRIME DP - Unbound Medicine ER -